Reprint
Human African Trypanosomiasis (Sleeping Sickness)
The Road to Elimination Revisited—Achievements and Remaining Challenges
Edited by
June 2020
280 pages
- ISBN978-3-03928-963-9 (Paperback)
- ISBN978-3-03928-964-6 (PDF)
This book is a reprint of the Special Issue Human African Trypanosomiasis (Sleeping Sickness): The Road to Elimination Revisited—Achievements and Remaining Challenges that was published in
Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Summary
As it is a goal to eliminate human African trypanosomiasis (HAT; sleeping sickness) as a public health problem by 2020 and interrupt transmission by 2030, this is a good moment to reflect on what we have achieved, what we want to achieve, and what could get in our way. HAT has a reputation for spectacular reappearances, and the latest peak of 40,000 reported and over 300,000 estimated cases only dates back to 1998. Efforts of the WHO and partners as well as the development of simpler and much better-tolerated treatments, improved diagnostics, and vector control tools made it possible to reduce this number by 95%. Case identification and confirmation remain complex and require specific skills, treatment remains error-prone and reports on long-term survivors have emerged, and the relevance of the animal reservoir for T. b. gambiense HAT needs clarification. In addition, to win the “end game” against this massively stigmatized disease, the human factor will play a key role. This Special Issue addresses many of the burning topics about disease elimination in its 12 research and 7 review articles and one case study. The papers critically reflect the approaches used, investigate the mentioned challenges, and propose novel approaches and interventions from various points of view.
Format
- Paperback
License
© 2020 by the authors; CC BY-NC-ND license
Keywords
(+)-spectaline; iso-6-spectaline; Trypanosoma brucei rhodesiense; autophagy; apoptosis; cross-talk; trypanosomosis; iron; transferrin; transferrin receptor; nutritional immunity; flagellar pocket; Human African Trypanosomiasis (HAT); mydriasis; neurological signs; eradication; re-emergence; human African trypanosomiasis; treatment; melarsoprol; adverse event; encephalopathy; human leukocyte antigen; association study; Human African Trypanosomiasis (HAT); disease elimination; disease eradication; frontline workers; DR Congo; mobile screening; qualitative methods; human African trypanosomiasis; sequelae; serology; treatment; oligosymptomatic HAT; product development partnerships; research and development; medical innovation; donor policy; African trypanosomiasis; sleeping sickness; human African trypanosomiasis; trypanosoma brucei; drugs; drug resistance; history; human Africa trypanosomiasis; fexinidazole; home-based treatment; patient-centred care; Uganda; elimination; sleeping sickness; human African trypanosomiasis; T. b. gambiense; g-HAT; T. b. rhodesiense; r-HAT; elimination; neglected tropical diseases; fexinidazole; Trypanosoma brucei; human African trypanosomiasis; drug discovery; high-throughput screening; blood–brain barrier; brain permeability; pharmacology; phenotypic drug screening; Haemoparasites; human African trypanosomiasis; elimination; animal reservoirs; sleeping sickness; drug discovery; Trypanosoma growth inhibitors; human African trypanosomiasis; sleeping sickness; elimination; chemotherapy; fexinidazole; pafuramidine; acoziborole; African sleeping sickness; development of treatment; suramin; medical history; political history; human African trypanosomiasis; clinical research; health system strengthening; South Sudan; human African trypanosomiasis; diagnosis; symptoms; treatment-seeking; case detection; elimination; embodiment; expertise; serendipity; CATT positive serological suspects; active follow-up strategy; human African trypanosomiasis; n/a